Oulaphone/AdobeStockCONFERENCE REPORTERInvestigators presented new phase 3 data on seltorexant compared with quetiapine extended release (XR) as adjunctive treatment for major depressive disorder (MDD) with insomnia symptoms at the 2025 Psych Congress in San Diego, CA. Participants aged 18-74 were randomly assigned (1:1) to receive either seltorexant or quetiapine XR while continuing use of their background SSRI/SNRI. At week 26, seltorexant showed a numerically greater response rate (57.4%) than quetiapine XR (53.4%), but this difference was not statistically significant (4.0% [95% CI: -3.3, 11.3]). Treatment-emergent adverse events (≥5% of participants) that were 2 times as common with quetiapine XR compared with seltorexant were somnolence, increased weight, and dry mouth. Seltorexant versus quetiapine extended release as adjunctive treatment in major depressive disorder with insomnia symptoms: phase 3 trial.